在沙特阿拉伯，iGlarLixi 对在日常实践中使用口服抗糖尿病药物和基础胰岛素或不使用基础胰岛素的未达到最佳控制水平的 T2D 患者的实际效果（EMPOWER 研究）

Q3 Medicine Endocrine and Metabolic Science Pub Date : 2024-01-27 DOI:10.1016/j.endmts.2024.100164

Anwar Jammah , Nagwa Roushdy , Mohamed Gamil , Nidal Abu Diab , Naglaa Abdelmonaem , Saher Safarini , Mohamed Gadallah , Nedal Abu Zaid , Yahya Shihadeh , Mohamed Saeed , Jamaa Sadik , Yasser Akil

{"title":"在沙特阿拉伯，iGlarLixi 对在日常实践中使用口服抗糖尿病药物和基础胰岛素或不使用基础胰岛素的未达到最佳控制水平的 T2D 患者的实际效果（EMPOWER 研究）","authors":"Anwar Jammah , Nagwa Roushdy , Mohamed Gamil , Nidal Abu Diab , Naglaa Abdelmonaem , Saher Safarini , Mohamed Gadallah , Nedal Abu Zaid , Yahya Shihadeh , Mohamed Saeed , Jamaa Sadik , Yasser Akil","doi":"10.1016/j.endmts.2024.100164","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>The prevalence of type 2 diabetes mellitus (T2DM) has increased in Saudi Arabia over recent decades, with current estimates showing that 19% of adults have T2DM. There is a need to confirm the clinical outcomes and safety of iGlarLixi in the routine clinical practice setting.</p></div><div><h3>Methods</h3><p>A multicenter retrospective non-comparative study was conducted on 224 people with T2DM on Oral anti-diabetics (OADs) or in combination with basal insulin who initiated treatment with iGlarLixi in Saudi Arabia. Data of at least 180 days (± 30 days) before and after initiating iGlarLixi were retrieved.</p></div><div><h3>Results</h3><p>Mean HbA1c significantly decreased after iGlarLixi start, with a mean reduction of 1.6% at six months. The mean reduction in the FPG was −38.8 (95% CI -46.5 to −31.1, <em>p</em> < 0.001). The weight dropped from 86.17 kg to 83.33 kg after 6 months post-iGlarLixi initiation [mean reduction = −2.86, <em>P</em> < 0.001]. The incidence of reported hypoglycemia, symptomatic documented and/or severe cases, decreased from 0.513 (95% CI 0.33 to 0.76) per person-year at baseline to 0.002 (95% CI 0.001 to 0.011) six months after iGlarLixi.</p></div><div><h3>Conclusion</h3><p>iGlarLixi is effective and well tolerated for improved glycemic control in patients with advanced therapy from OADs or insulin in Saudi Arabia.</p></div>","PeriodicalId":34427,"journal":{"name":"Endocrine and Metabolic Science","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666396124000086/pdfft?md5=173ff472e5e95cc4614cb64f05323614&pid=1-s2.0-S2666396124000086-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Real-world effectiveness of iGlarLixi in individuals with T2D sub-optimally controlled on oral anti-diabetic drugs with or without basal insulin in daily practice in Saudi Arabia (EMPOWER study)\",\"authors\":\"Anwar Jammah , Nagwa Roushdy , Mohamed Gamil , Nidal Abu Diab , Naglaa Abdelmonaem , Saher Safarini , Mohamed Gadallah , Nedal Abu Zaid , Yahya Shihadeh , Mohamed Saeed , Jamaa Sadik , Yasser Akil\",\"doi\":\"10.1016/j.endmts.2024.100164\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Introduction</h3><p>The prevalence of type 2 diabetes mellitus (T2DM) has increased in Saudi Arabia over recent decades, with current estimates showing that 19% of adults have T2DM. There is a need to confirm the clinical outcomes and safety of iGlarLixi in the routine clinical practice setting.</p></div><div><h3>Methods</h3><p>A multicenter retrospective non-comparative study was conducted on 224 people with T2DM on Oral anti-diabetics (OADs) or in combination with basal insulin who initiated treatment with iGlarLixi in Saudi Arabia. Data of at least 180 days (± 30 days) before and after initiating iGlarLixi were retrieved.</p></div><div><h3>Results</h3><p>Mean HbA1c significantly decreased after iGlarLixi start, with a mean reduction of 1.6% at six months. The mean reduction in the FPG was −38.8 (95% CI -46.5 to −31.1, <em>p</em> < 0.001). The weight dropped from 86.17 kg to 83.33 kg after 6 months post-iGlarLixi initiation [mean reduction = −2.86, <em>P</em> < 0.001]. The incidence of reported hypoglycemia, symptomatic documented and/or severe cases, decreased from 0.513 (95% CI 0.33 to 0.76) per person-year at baseline to 0.002 (95% CI 0.001 to 0.011) six months after iGlarLixi.</p></div><div><h3>Conclusion</h3><p>iGlarLixi is effective and well tolerated for improved glycemic control in patients with advanced therapy from OADs or insulin in Saudi Arabia.</p></div>\",\"PeriodicalId\":34427,\"journal\":{\"name\":\"Endocrine and Metabolic Science\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-01-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2666396124000086/pdfft?md5=173ff472e5e95cc4614cb64f05323614&pid=1-s2.0-S2666396124000086-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Endocrine and Metabolic Science\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2666396124000086\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Endocrine and Metabolic Science","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666396124000086","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

导言近几十年来，沙特阿拉伯的 2 型糖尿病（T2DM）患病率不断上升，目前估计有 19% 的成年人患有 T2DM。这项多中心回顾性非比较研究的对象是沙特阿拉伯的 224 名口服抗糖尿病药（OAD）或与基础胰岛素合用的 T2DM 患者，他们都开始使用 iGlarLixi 进行治疗。结果开始使用 iGlarLixi 后，平均 HbA1c 显著下降，6 个月时平均下降 1.6%。FPG 的平均降幅为 -38.8 (95% CI -46.5 to -31.1, p < 0.001)。使用 iGlarLixi 6 个月后，体重从 86.17 千克降至 83.33 千克[平均降幅 = -2.86，P < 0.001]。报告的低血糖、有症状和/或严重病例的发生率从基线时的每人每年 0.513 例（95% CI 0.33 至 0.76 例）下降到 iGlarLixi 使用 6 个月后的 0.002 例（95% CI 0.001 至 0.011 例）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Real-world effectiveness of iGlarLixi in individuals with T2D sub-optimally controlled on oral anti-diabetic drugs with or without basal insulin in daily practice in Saudi Arabia (EMPOWER study)

Introduction

The prevalence of type 2 diabetes mellitus (T2DM) has increased in Saudi Arabia over recent decades, with current estimates showing that 19% of adults have T2DM. There is a need to confirm the clinical outcomes and safety of iGlarLixi in the routine clinical practice setting.

Methods

A multicenter retrospective non-comparative study was conducted on 224 people with T2DM on Oral anti-diabetics (OADs) or in combination with basal insulin who initiated treatment with iGlarLixi in Saudi Arabia. Data of at least 180 days (± 30 days) before and after initiating iGlarLixi were retrieved.

Results

Mean HbA1c significantly decreased after iGlarLixi start, with a mean reduction of 1.6% at six months. The mean reduction in the FPG was −38.8 (95% CI -46.5 to −31.1, p < 0.001). The weight dropped from 86.17 kg to 83.33 kg after 6 months post-iGlarLixi initiation [mean reduction = −2.86, P < 0.001]. The incidence of reported hypoglycemia, symptomatic documented and/or severe cases, decreased from 0.513 (95% CI 0.33 to 0.76) per person-year at baseline to 0.002 (95% CI 0.001 to 0.011) six months after iGlarLixi.